

From Tummy to Mommy: The Impact of Inflammatory Bowel Disease on Pregnancy

Devangkumar Lakhani¹, Utsav Vaghani², Vatsalkumar Jetani³, Ishita Sanghani⁴, Vidit Jogani⁵, Niralkumar Ghevariya⁶, and Akash Patel^{7*}

¹Gujarat Medical Education and Research Society, Gotri, Vadodara, India.

²Smt. N.H.L. Municipal Medical College, Ahmedabad, India.

³Gujarat Medical Education and Research Society, Valsad, India.

⁴MGM Medical College, Aurangabad, India.

⁵UNM Children Hospital, Surat, India

⁶Surat municipal institute of medical education and research, Surat, India.

⁷Eisenhower Medical Centre, USA

*Corresponding Author

Akash Patel, Eisenhower Medical Centre, USA

Submitted: 2024, Jan 05; Accepted: 2024, Feb 09; Published: 2024, Feb 14

Citation: Lakhani, D., Vaghani, U., Jetani, V., Sanghani, I., Jogani, V., et al. (2024). From Tummy to Mommy: The Impact of Inflammatory Bowel Disease on Pregnancy. *Japan J Med Sci*, 2(1), 01-05.

Abstract

This review examines the relationship between Inflammatory Bowel Disease (IBD) and pregnancy. Focusing on women of reproductive age, it explores the epidemiological impact, management challenges, and pharmacological considerations of IBD in pregnancy. The review highlights the importance of maintaining disease remission, the role of hormonal and immunological changes, and the necessity of a multidisciplinary approach for optimal maternal and fetal outcomes. Additionally, it discusses the significance of diet and the microbiome in managing pregnant IBD patients and outlines current medical guidelines and recommendations. The review concludes by suggesting areas for future research, emphasizing the need for comprehensive, individualized, and evidence-based care for pregnant women with IBD.

1. Introduction

Inflammatory bowel disease (IBD) is a chronic, often debilitating condition primarily manifesting as ulcerative colitis (UC) and Crohn's disease (CD) that afflicts the gastrointestinal tract [1]. Notably, this disorder disproportionately affects women in their reproductive years, thus rendering its implications for pregnancy of paramount importance [2]. This review aims to provide an encompassing examination of the complex interplay between IBD and pregnancy, elucidating its epidemiological impact, pharmacological management, and necessitating an integrated approach to optimize maternal and fetal outcomes.

Epidemiological data suggest that approximately 0.4% of pregnant women are diagnosed with either UC or CD, as per a population-based cohort study in New South Wales, Australia [1]. Contrary to some expectations, a comprehensive meta-analysis encompassing nearly 7,000 pregnant IBD patients under biologic treatment revealed no elevated risk of adverse pregnancy

outcomes compared to the general populace [3]. Nonetheless, there is conflicting literature documenting increased rates of premature delivery, low birth weight, stillbirth, cesarean section, and congenital malformations in the IBD cohort [4,5].

Treatment paradigms during pregnancy further complicate the landscape. Pharmacological management is essential for disease control but must be judiciously balanced against potential teratogenic effects. Several studies underscore the general safety of IBD medications, even potent biologics like infliximab and adalimumab, during gestation [6-8]. However, maternal reluctance toward maintaining drug regimens throughout pregnancy persists, fuelling the need for more definitive safety profiles [9]. Complications such as heightened risks of venous thromboembolism and the exacerbation of IBD symptoms during pregnancy make the condition particularly exigent to manage [10,11]. Therefore, examining the impacts of IBD in the specific context of pregnancy is critical for not only maternal and fetal

well-being but also for contributing to therapeutic innovations and evidence-based medical guidelines.

2. Hormonal and Immunological Changes During Pregnancy and IBD:

Pregnancy can have significant effects on the pathogenesis and management of IBD [12]. Pregnancy is associated with alterations in immune responses and disease progression [12]. Hormonal changes, such as increased concentrations of progesterone, can affect local immune responses and increase the risk of infection [12]. Optimal management of IBD before and during pregnancy is crucial for favourable maternal and neonatal outcomes [13]. Studies have shown that active IBD during preconception and pregnancy can adversely impact fertility, increase the risk of disease exacerbations, and lead to poor outcomes [14,15]. However, the impact of pregnancy on the course of IBD is variable, with some women experiencing worsening flares, stable disease, or improvement [16]. It is important to maintain disease remission during and before pregnancy to minimize complications [15].

The immune system undergoes changes during pregnancy to establish immune tolerance towards the foetus while maintaining effective immune responses against infections [17]. Hormones, such as oestrogen and progesterone, play a role in modulating immune responses during pregnancy [17]. These hormonal changes contribute to the induction of immune tolerance and the development and function of regulatory B cells [18]. Additionally, glucocorticoid receptors in T cells mediate protection from autoimmunity during pregnancy [19]. The endocrine milieu and CD4 T-lymphocyte polarization also play a role in the regulation of the immune system during pregnancy [20].

3. Clinical Trajectories of Inflammatory Bowel Disease in Pregnancy

Understanding the clinical ramifications of IBD is crucial for optimal maternal and fetal outcomes. Data indicate that IBD remission at the time of conception and its maintenance throughout gestation are pivotal for favourable pregnancy outcomes [2]. Conversely, active IBD has been linked to increased risks such as prematurity, low birth weight, and higher rates of caesarean sections [21,22]. The clinical trajectory of IBD during pregnancy appears to be largely influenced by its activity at conception [23]. Given the association between active disease states and adverse outcomes like miscarriages and preterm deliveries, stringent disease management is imperative [15]. A multidisciplinary model of care is requisite, involving gastroenterologists, obstetricians, and other healthcare professionals. Such an approach facilitates shared decision-making, particularly concerning critical issues like medication regimens, surgical interventions, and psychosocial well-being [14]. Beyond the physiological implications, IBD also poses psychosocial challenges that may affect reproductive choices and maternal well-being [24]. Addressing these aspects is integral to a holistic approach to patient care [25].

4. Pharmacological Considerations in Managing IBD During Pregnancy

In the management of IBD during pregnancy, a nuanced approach

to pharmacotherapy is essential for optimizing both maternal and fetal outcomes [26,27]. First-line agents like amino salicylates are generally well-tolerated and effective for mild-to-moderate disease, whereas glucocorticoids serve for induction of remission in more severe cases but warrant caution for potential adverse effects [28, 29]. Adjunct therapies including antibiotics and immunomodulators like mercaptopurine may be considered, the former especially in cases of localized infection or abscess but with noted caution for its association with early-onset IBD in offspring [30-32]. Biologic agents, primarily those targeting TNF α , have exhibited transformative efficacy and a reassuring safety profile during pregnancy [26, 28]. Emerging therapies such as other biologics and JAK inhibitors offer alternative avenues, particularly in refractory cases, although their safety profiles during gestation require further elucidation [33-36]. The therapeutic strategy mandates individualized treatment plans, meticulous disease monitoring, and prompt interventions, integrated through a patient-centric model that considers the complexities of the disease states and the safety profiles of available medications [6,25,37, 38].

5. Role of Diet During Pregnancy in IBD Patients

The centrality of diet in managing Inflammatory Bowel Disease (IBD) during pregnancy extends beyond its role in general disease modulation; it has direct implications for both maternal and fetal health outcomes [39,40]. Protein-calorie malnutrition is a recognized concern, linking poor maternal weight gain to compromised fetal metrics such as low birth weight and growth restriction [29, 41]. Specialized dietary regimens, encompassing low-FODMAP diets, specific carbohydrate diets, and low-fat diets, not only offer symptom alleviation but also potentially influence gut microbiota and disease activity, thereby contributing to more effective disease management during pregnancy [40,42].

The pertinence of dairy protein intake in IBD pregnancies necessitates further empirical scrutiny, although avoidance behaviours have been documented [43]. This is set against a backdrop of extant uncertainties surrounding pharmacotherapy for IBD during pregnancy, which require individualized counselling and risk-benefit assessments to harmonize disease control with maternal and fetal safety [38, 44]. In sum, an integrated approach that synergizes dietary considerations with pharmaceutical interventions is imperative for optimizing the health trajectories of both mother and fetus in the context of IBD [45].

6. Role of Microbiome in Pregnant IBD Patients

The role of the microbiome in managing IBD is further complicated by pregnancy, underscoring the urgency for targeted research [46,47]. Dysbiosis, characterized by altered microbiome composition, is often observed in IBD patients and has been found to experience additional shifts during pregnancy, specifically in the gut and vaginal microbiomes [48]. These shifts could have significant implications for both maternal and fetal health. Additionally, the microbiome is posited to act as a genetic risk modulator in IBD and plays a role in altering cytokine patterns during pregnancy, such as the normalization of serum proinflammatory cytokine levels during the later stages [49,50].

Clinically, this emerging understanding suggests avenues for intervention. For instance, probiotic supplements containing specific bacterial genera like *Bifidobacterium*, *Faecal bacterium*, and *Lactobacillus* might restore gut microbiome balance and improve outcomes in pregnant IBD patients [51]. Similarly, microbiome-targeted therapeutics such as fiber and prebiotics have shown promise in balancing the gut microbiome, potentially benefiting pediatric IBD cases [52]. By dissecting these microbiome shifts during pregnancy, healthcare providers can optimize disease management strategies to maximize positive outcomes for both mother and baby.

7. Managing Pregnancy in IBD: Recommendations and Guidelines

Medical guidelines advocate for continued treatment during pregnancy, emphasizing that the benefits generally outweigh potential risks [26, 44,53]. Nonetheless, fears surrounding IBD medications during pregnancy may exist, necessitating clear communication between healthcare providers and patients [27]. Moreover, preventative measures including vaccinations, high-risk obstetric care, and lifestyle modifications are strongly recommended [54-56]. Particular vigilance is advised for venous thromboembolism (VTE), with anticoagulant thromboprophylaxis suggested for hospitalized pregnant IBD patients [53].

8. Future Research Directions

• Despite significant advancements in understanding the intricate relationship between Inflammatory Bowel Disease (IBD) and pregnancy, several avenues for future research remain to be explored:

• Long-term maternal and fetal outcomes: Most studies focus on the immediate implications of IBD during pregnancy, with limited longitudinal data that follow both maternal and child health years post-partum.

• Personalized treatment algorithms: Investigating genetic, epigenetic, and microbial markers could potentially lead to more individualized treatment plans that optimize maternal and fetal outcomes.

• Mental health assessment: The psychosocial impact of IBD during pregnancy remains under-explored. Future research could address this gap by examining the mental well-being of pregnant IBD patients and devising coping mechanisms and interventions.

• Safety profiles of new medications: With the introduction of newer classes of drugs, such as JAK inhibitors and newer biologics, more research is needed to establish their safety profiles during pregnancy.

• Nutritional interventions: Understanding the role of specific dietary patterns and supplements, such as prebiotics and probiotics, in managing IBD symptoms during pregnancy warrants further scrutiny.

• Telemedicine and remote monitoring: In the age of digital healthcare, the efficacy of telemedicine in managing IBD during

pregnancy needs evaluation.

• Role of the Microbiome: A deeper understanding of microbiome shifts, their influence on IBD and pregnancy outcomes, and potential interventions like fecal microbiota transplants could be transformative.

• Environmental factors: Research on the impact of external factors like stress, exposure to pollution, and lifestyle habits can offer insights into disease modulation during pregnancy.

• Integration of multidisciplinary care: Studies assessing the efficacy of collaborative healthcare models that involve gastroenterologists, obstetricians, dieticians, and psychologists in the care of pregnant IBD patients could significantly inform best practices.

• Global disparities: There is a need to understand how different socio-cultural settings influence the management and outcomes of IBD in pregnancy, particularly in low- and middle-income countries.

9. Conclusion

Inflammatory Bowel Disease poses complex challenges in the context of pregnancy, affecting both maternal and fetal health. The current body of literature presents a multifaceted view, discussing epidemiological impacts, hormonal and immunological changes, clinical trajectories, pharmacological considerations, dietary roles, and the implications of microbiome shifts. While strides have been made in pharmacological management, identifying the factors influencing disease course, and advocating multidisciplinary care models, numerous gaps and future research opportunities remain. By filling these gaps, healthcare providers can aim for a more comprehensive, individualized, and evidence-based approach to manage IBD in pregnant patients effectively. The ultimate goal is to enhance the quality of life for mothers-to-be with IBD and ensure the well-being of their offspring.

References

1. Shand, A. W., Chen, J. S., Selby, W., Solomon, M., & Roberts, C. L. (2016). Inflammatory bowel disease in pregnancy: a population-based study of prevalence and pregnancy outcomes. *BJOG: An International Journal of Obstetrics & Gynaecology*, *123*(11), 1862-1870.
2. Mahadevan, U., Sandborn, W. J., Li, D. K., Hakimian, S., Kane, S., & Corley, D. A. (2007). Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. *Gastroenterology*, *133*(4), 1106-1112.
3. Nielsen, O. H., Gubatan, J. M., Juhl, C. B., Streett, S. E., & Maxwell, C. (2022). Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*, *20*(1), 74-87.
4. Poturoglu, S., Ormeci, A. C., & Duman, A. E. (2016). Treatment of pregnant women with a diagnosis of inflammatory bowel disease. *World journal of gastrointestinal pharmacology and therapeutics*, *7*(4), 490.

5. Mozaffari, S., Abdolghaffari, A. H., Nikfar, S., & Abdollahi, M. (2015). Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. *Human & experimental toxicology*, 34(5), 445-459.
6. Keller, M. S., Mosadeghi, S., Cohen, E. R., Kwan, J., & Spiegel, B. M. R. (2018). Reproductive health and medication concerns for patients with inflammatory bowel disease: thematic and quantitative analysis using social listening. *Journal of Medical Internet Research*, 20(6), e206.
7. Pinder, M., Lummis, K., & Selinger, C. P. (2016). Managing inflammatory bowel disease in pregnancy: current perspectives. *Clinical and experimental gastroenterology*, 325-335.
8. Mourabet, M. E., El-Hachem, S., Harrison, J. R., & Binion, D. G. (2010). Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review. *Current drug targets*, 11(2), 234-241.
9. Cao, R. H., & Grimm, M. C. (2021). Pregnancy and medications in inflammatory bowel disease. *Obstetric Medicine*, 14(1), 4-11.
10. Hansen, A. T., Erichsen, R., Horváth-Puhó, E., & Sørensen, H. T. (2017). Inflammatory bowel disease and venous thromboembolism during pregnancy and the postpartum period. *Journal of Thrombosis and Haemostasis*, 15(4), 702-708.
11. Grgić, D., Čuković Čavka, S., Elvedić Gašparović, V., Turk, N., Brinar, M., Marušić, Z., & Krznarić, Ž. (2021). Pregnancy-onset acute severe colitis after in vitro fertilization embryo transfer. *Case reports in gastroenterology*, 14(3), 477-482.
12. Robinson, D. P., & Klein, S. L. (2012). Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis. *Hormones and behavior*, 62(3), 263-271.
13. Nguyen, G. C., Seow, C. H., Maxwell, C., Huang, V., Leung, Y., Jones, J., ... & Paterson, W. (2016). The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. *Gastroenterology*, 150(3), 734-757.
14. Williams, A. J., Karimi, N., Chari, R., Connor, S., De Vera, M. A., Dieleman, L. A., ... & Huang, V. (2021). Shared decision making in pregnancy in inflammatory bowel disease: design of a patient orientated decision aid. *BMC gastroenterology*, 21(1), 1-18.
15. Vermeire, S., Carbonnel, F., Coulie, P. G., Geenen, V., Hazes, J. M., Masson, P. L., ... & Louis, E. (2012). Management of inflammatory bowel disease in pregnancy. *Journal of Crohn's and Colitis*, 6(8), 811-823.
16. Mahadevan, U., & Matro, R. (2015). Care of the pregnant patient with inflammatory bowel disease. *Obstetrics & Gynecology*, 126(2), 401-412.
17. Papapavlou, G., Hellberg, S., Raffetseder, J., Brynhildsen, J., Gustafsson, M., Jenmalm, M. C., & Ernerudh, J. (2021). Differential effects of estradiol and progesterone on human T cell activation in vitro. *European Journal of Immunology*, 51(10), 2430-2440.
18. Muzzio, D., Zygmunt, M., & Jensen, F. (2014). The role of pregnancy-associated hormones in the development and function of regulatory B cells. *Frontiers in endocrinology*, 5, 39.
19. Engler, J. B., Kursawe, N., Solano, M. E., Patas, K., Wehrmann, S., Heckmann, N., ... & Friese, M. A. (2017). Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy. *Proceedings of the National Academy of Sciences*, 114(2), E181-E190.
20. Polese, B., Gridelet, V., Araklioti, E., Martens, H., Perrier d'Hauterive, S., & Geenen, V. (2014). The endocrine milieu and CD4 T-lymphocyte polarization during pregnancy. *Frontiers in endocrinology*, 5, 106.
21. Meyer, A., Drouin, J., Weill, A., Carbonnel, F., & Dray-Spira, R. (2020). Pregnancy in women with inflammatory bowel disease: a French nationwide study 2010-2018. *Alimentary Pharmacology & Therapeutics*, 52(9), 1480-1490.
22. Vestergaard, T., Julsgaard, M., Røsoek, J. F., Vestergaard, S. V., Helmig, R. B., Friedman, S., & Kelsen, J. (2023). Predictors of disease activity during pregnancy in women with inflammatory bowel disease—A Danish cohort study. *Alimentary Pharmacology & Therapeutics*, 57(3), 335-344.
23. Hosseini-Carroll, P., Mutyala, M., Seth, A., Nageeb, S., Soliman, D., Boktor, M., ... & Alexander, J. S. (2015). Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management. *World journal of gastrointestinal pharmacology and therapeutics*, 6(4), 156.
24. Purewal, S., Chapman, S., Czuber-Dochan, W., Selinger, C., Steed, H., & Brookes, M. J. (2018). Systematic review: the consequences of psychosocial effects of inflammatory bowel disease on patients' reproductive health. *Alimentary Pharmacology & Therapeutics*, 48(11-12), 1202-1212.
25. Flanagan, E. K., Richmond, J., Thompson, A. J., Desmond, P. V., & Bell, S. J. (2021). Addressing pregnancy-related concerns in women with inflammatory bowel disease: Insights from the patient's perspective. *JGH Open*, 5(1), 28-33.
26. Biedermann, L., Rogler, G., Vavricka, S. R., Seibold, F., & Seirafi, M. (2012). Pregnancy and breastfeeding in inflammatory bowel disease. *Digestion*, 86(Suppl. 1), 45-54.
27. Hoffmann, P., Krueger, J., Bashlekova, T., Rupp, C., Baumann, L., & Gauss, A. (2022). Pregnancy with inflammatory bowel disease: Outcomes for mothers and their children at a European tertiary care center. *Journal of Obstetrics and Gynaecology Research*, 48(3), 621-633.
28. de Lima-Karagiannis, A., Zelinkova-Detkova, Z., & Van Der Woude, C. J. (2016). The effects of active IBD during pregnancy in the era of novel IBD therapies. *Official journal of the American College of Gastroenterology | ACG*, 111(9), 1305-1312.
29. Bell, S. J., & Flanagan, E. K. (2019). Updates in the management of inflammatory bowel disease during pregnancy. *Med J Aust*, 210(6), 276-80.
30. Örtqvist, A. K., Lundholm, C., Halfvarson, J., Ludvigsson, J. F., & Almqvist, C. (2018). Fetal and early life antibiotics exposure and very early onset inflammatory bowel disease: a population-based study. *Gut*, gutjnl-2017.
31. Santana, P. T., Rosas, S. L. B., Ribeiro, B. E., Marinho, Y., & de Souza, H. S. (2022). Dysbiosis in inflammatory bowel disease: pathogenic role and potential therapeutic targets.

- International journal of molecular sciences*, 23(7), 3464.
32. Agrawal, M., Poulsen, G., Colombel, J. F., Allin, K. H., & Jess, T. (2022). Maternal antibiotic exposure during pregnancy and risk of IBD in offspring: a population-based cohort study. *Gut*.
 33. Moon, S. Y., Kim, K. D., Yoo, J., Lee, J. H., & Hwangbo, C. (2021). Phytochemicals targeting JAK–STAT pathways in inflammatory bowel disease: insights from animal models. *Molecules*, 26(9), 2824.
 34. Chen, W., Chen, H., Fu, S., Lin, X., Zheng, Z., & Zhang, J. (2021). Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights. *Bioprocess and Biosystems Engineering*, 44, 929-939.
 35. Dudek, P., Fabisiak, A., Zatorski, H., Malecka-Wojcieszko, E., & Talar-Wojnarowska, R. (2021). Efficacy, safety and future perspectives of JAK inhibitors in the IBD treatment. *Journal of Clinical Medicine*, 10(23), 5660.
 36. Lei, H., Crawford, M. S. S., & McCole, D. F. (2021). JAK-STAT Pathway Regulation of Intestinal Permeability: Pathogenic Roles and Therapeutic Opportunities in Inflammatory Bowel Disease. *Pharmaceuticals*, 14(9), 840.
 37. Lee, S., Seow, C. H., Adhikari, K., & Metcalfe, A. (2020). Pregnant women with IBD are more likely to be adherent to biologic therapies than other medications. *Alimentary pharmacology & therapeutics*, 51(5), 544-552.
 38. Rao, A. K., Zikos, T. A., Garay, G., Lee, K. E., & Streett, S. E. (2021). Patients report infrequent counseling by physicians and inadequate knowledge about inflammatory bowel disease and reproductive health issues. *American Journal of Perinatology*.
 39. Lichtenstein, G. R. (2008). A meta-analysis on the influence of inflammatory bowel disease on pregnancy Cornish J, Tan E, Teare J, et al (St Mary's Hosp, London) *Gut* 56: 830-837, 2007. Year Book of Gastroenterology, 2008, 160-161.
 40. Sugihara, K., & Kamada, N. (2021). Diet–microbiota interactions in inflammatory bowel disease. *Nutrients*, 13(5), 1533.
 41. Smith, M. A., & Sanderson, J. D. (2010). Management of inflammatory bowel disease in pregnancy. *Obstetric Medicine*, 3(2), 59-64.
 42. Simões, C. D., Maganinho, M., & Sousa, A. S. (2022). FODMAPs, inflammatory bowel disease and gut microbiota: updated overview on the current evidence. *European journal of nutrition*, 1-12.
 43. Bengtson, M. B., Haugen, M., Brantsæter, A. L., Aamodt, G., & Vatn, M. H. (2020). Intake of dairy protein during pregnancy in IBD and risk of SGA in a Norwegian population-based mother and child cohort. *BMC gastroenterology*, 20, 1-11.
 44. Dignass, A. U., Hartmann, F., Sturm, A., & Stein, J. (2009). Management of inflammatory bowel diseases during pregnancy. *Digestive diseases*, 27(3), 341-346.
 45. Korelitz, B. I. (1998). Inflammatory bowel disease and pregnancy. *Gastroenterology Clinics of North America*, 27(1), 213-224.
 46. Morgan, X. C., Tickle, T. L., Sokol, H., Gevers, D., Devaney, K. L., Ward, D. V., ... & Huttenhower, C. (2012). Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome biology*, 13(9), 1-18.
 47. Aldars-Garcia, L., Chaparro, M., & Gisbert, J. P. (2021). Systematic review: the gut microbiome and its potential clinical application in inflammatory bowel disease. *Microorganisms*, 9(05), 977.
 48. Hill, J. E., Peña-Sánchez, J. N., Fernando, C., Freitas, A. C., Withana Gamage, N., & Fowler, S. (2022). Composition and stability of the vaginal microbiota of pregnant women with inflammatory bowel disease. *Inflammatory Bowel Diseases*, 28(6), 905-911.
 49. Sharma, A., Szymczak, S., Rühlemann, M., Freitag-Wolf, S., Knecht, C., Enderle, J., ... & Dempfle, A. (2022). Linkage analysis identifies novel genetic modifiers of microbiome traits in families with inflammatory bowel disease. *Gut Microbes*, 14(1), 2024415.
 50. van der Giessen, J., Binyamin, D., Belogolovski, A., Frishman, S., Tenenbaum-Gavish, K., Hadar, E., ... & Fuhler, G. M. (2019). Modulation of cytokine patterns and microbiome during pregnancy in IBD. *Gut*.
 51. Dong, L. N., Wang, M., Guo, J., & Wang, J. P. (2019). Role of intestinal microbiota and metabolites in inflammatory bowel disease. *Chinese medical journal*, 132(13), 1610-1614.
 52. Healey, G. R., Celiberto, L. S., Lee, S. M., & Jacobson, K. (2020). Fiber and prebiotic interventions in pediatric inflammatory bowel disease: what role does the gut microbiome play?. *Nutrients*, 12(10), 3204.
 53. Selinger, C., Carey, N., Cassere, S., Nelson-Piercy, C., Fraser, A., Hall, V., ... & Glanville, T. (2021). Standards for the provision of antenatal care for patients with inflammatory bowel disease: guidance endorsed by the British Society of Gastroenterology and the British Maternal and Fetal Medicine Society. *Frontline Gastroenterology*, 12(3), 182-187.
 54. Macaluso, F. S., Liguori, G., & Galli, M. (2021). Vaccinations in patients with inflammatory bowel disease. *Digestive and Liver Disease*, 53(12), 1539-1545.
 55. Ng, S. W., & Mahadevan, U. (2014, March). My treatment approach to management of the pregnant patient with inflammatory bowel disease. In *Mayo Clinic Proceedings* (Vol. 89, No. 3, pp. 355-360). Elsevier.
 56. Weissman, S., Systrom, H. K., Bangolo, A., Elias, D., Awasi, M., Zahdeh, T., ... & Feuerstein, J. D. (2023). Health Maintenance and Preventative Care in Inflammatory Bowel Disease: A Systematic Review of the Overall Quality of Societal Recommendations. *Journal of Clinical Gastroenterology*, 57(4), 325-334.

Copyright: ©2024 Akash Patel, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.